LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004

Abstract

Open access

Peer reviewed

E. Swisher, A. Miller, E. Kohn, M. Brady, M. Radke, C. Pennil, N. Khasnavis, J. Buscema, W. Tew, C. Muller, …

Annals of oncology, Vol.32, pp.S1309-S1309

09/2021

DOI: 10.1016/j.annonc.2021.08.2111

Files and links (1)

url

https://doi.org/10.1016/j.annonc.2021.08.2111View

Published (Version of record) Open Access

Title: Subtitle: LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
Creators: E. Swisher - University of Washington
A. Miller - Roswell Park Cancer Institute
E. Kohn - National Cancer Institute
M. Brady - Roswell Park Cancer Institute
M. Radke - University of Washington
C. Pennil - University of Washington
N. Khasnavis - University of Washington
J. Buscema - Arizona Oncology
W. Tew - Memorial Sloan Kettering Cancer Center
C. Muller - University of New Mexico
E. Hill - University of Iowa
R. Moore - University of Rochester Medical Center
D. Michelin - Michigan Cancer Research Consortium
S. Waggoner - University Hospitals of Cleveland
M. Geller - University of Minnesota
K. Fujiwara - Saitama Medical University
S. D'Andre - Sutter Health
J. Liu - Dana-Farber Cancer Institute
M.J. Birrer - University of Arkansas for Medical Sciences
Resource Type: Abstract
Publication Details: Annals of oncology, Vol.32, pp.S1309-S1309
DOI: 10.1016/j.annonc.2021.08.2111
ISSN: 0923-7534
eISSN: 1569-8041
Publisher: Elsevier Ltd
Language: English
Date published: 09/2021
Academic Unit: Obstetrics and Gynecology
Record Identifier: 9984317104502771

55 Record Views